Physician profile
Stuart M Diamond
NPI 1174589709
$5,557.63
in general payments reported to CMS, 2019-2025
31 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $208 · 2021: $433 · 2022: $843 · 2023: $2,056 · 2024: $924 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,553 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,552.71 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,799.61 | 2023-2025 | Xeomin |
| Astellas Pharma US INC | $713.70 | 2019-2025 | Myrbetriq, Xtandi |
| Antares Pharma, INC. | $537.30 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $461.29 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $285.66 | 2023-2025 | Gemtesa |
| Teleflex LLC | $237.51 | 2020-2025 | Urolift, Solesta, Barrigel |
| Tolmar, INC. | $178.18 | 2023-2025 | Eligard, Jatenzo |
| Janssen Biotech, INC. | $175.53 | 2019-2025 | Erleada |
| Urovant Sciences INC | $172.63 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $133.28 | 2022-2024 | Prolaris |
| Halozyme INC | $129.37 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.51 | 2021-2025 | |
| Axonics, INC. | $86.02 | 2022-2023 | Axonics |
| Boston Scientific Corporation | $76.39 | 2020-2021 | |
| Tolmar Pharmaceuticals, INC. | $66.07 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $44.27 | 2023-2025 | Gyrus Acmi, Itind System |
| Verity Pharmaceuticals INC. | $38.97 | 2023-2025 | Trelstar, Tlando |
| Clarus Therapeutics INC. | $38.41 | 2021 | |
| Abbvie INC. | $36.63 | 2024-2025 | |
| C. R. Bard, INC. & Subsidiaries | $29.50 | 2022 | |
| Ferring Pharmaceuticals INC. | $29.01 | 2019-2024 | Adstiladrin |
| Myovant Sciences INC. | $25.36 | 2021-2022 | |
| Acelrx Pharmaceuticals, INC. | $22.42 | 2022 | |
| Revance Therapeutics, INC. | $20.95 | 2025 | Daxxify |
| Endo USA, INC. | $18.76 | 2025 | Aveed, Xiaflex |
| Olympus Corporation of The Americas | $14.91 | 2022 | |
| Laborie Medical Technologies Corp. | $14.09 | 2024 | Optilume Bph Drug Coated Balloon Catheter, Endosheath Technology |
| Medtronic USA, INC. | $14.00 | 2019 | |
| Coloplast Corp | $12.15 | 2019 | |
| Allergan, INC. | $11.94 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.